Study to Evaluate the Effect of Pasteurized Akkermansia Muciniphila (pAkk) on Complaints Related to IBS

Irritable Bowel Syndrome Clinical Trial

Official title:

Study to Evaluate the Effect of Pasteurized Akkermansia Muciniphila (pAkk) on Complaints Related to Irritable Bowel Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05348642
• Other study ID #: A-M/001322-2
• Status: Completed
• Phase: N/A
• Start date: July 21, 2022
• Est. completion date: January 6, 2023

Study information

• Verified date: March 2023
• Source: A-Mansia Biotech S.A.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Double-blind, randomised, placebo-controlled study to evaluate the benefit of pasteurized Akkermansia muciniphila in reducing complaints related to irritable bowel syndrome. Further objectives are to evaluate the beneficial potential of pAkk on any anxiety and depression complaints, as well as its safety and tolerability.

Description:

Irritable bowel syndrome (IBS) is one of the most common disorders of gut-brain interaction, globally affecting about 10% of the population. Typical predominant traits are abdominal pain and abnormal bowel habits. The use of probiotics in IBS has been continuously assessed; in recent systematic reviews and meta-analyses, single or combined probiotic strains were indicated to have beneficial effects and good tolerability in the affected population. pAkk has recently been assessed as a safe novel food ingredient. Beneficial effects and very good tolerability of pAkk have been reported in individuals with metabolic disorders. The objective of the present clinical study - a double-blind, randomised, placebo-controlled, parallel group design, explorative pilot 12-week nutritional study, is to assess the potential of pAkk in IBS management. The main study objective is then to evaluate the benefit of pAkk in reducing complaints related to irritable bowel syndrome. Further objectives are to evaluate the beneficial potential of pAkk on any anxiety and depression complaints, as well as its safety and tolerability. In total, 90 participants will be enrolled and will attend 4 study visits: one on site and 3 televisits.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: January 6, 2023
• Est. primary completion date: January 6, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Men and women from 18 to 70 years old

2. Meeting Rome-IV criteria for IBS:

Recurrent abdominal pain on average =1 day/ week in =3 months prior to study (with

symptom onset =6 months prior to study), associated with =2 of the following criteria:

• Related to defecation
• Associated with a change in frequency of stool
• Associated with a change in form (appearance) of stool

3. Consistent and stable body weight in the last 3 months prior to study (less than 5% self-reported change)

4. Having access to a smartphone or a computer with an internet access, either allowing a video call, and familiar with the use thereof (checked during the visit)

5. Subject's agreement to comply with study procedures, in particular:

• to take IP as recommended
• to avoid the use of other products which may influence the GI complaints during the study
• to keep the habitual dietary habits, type and level of physical activity (including any specific exercise such as e.g. yoga) as well as the level of caffeine or nicotine (if any)
• to complete the subject diary and study questionnaires

6. Women of childbearing potential:

• commitment to use contraception methods
• negative pregnancy testing (beta human chorionic gonadotropin test in urine)

7. Readiness not to participate in another clinical study during this study

Exclusion Criteria:

1. Self-reported known allergy or hypersensitivity to any of the components of the investigational product

2. Self-reported nocturnal GI complaints

3. Women of childbearing potential: self-reported GI complaints mainly related to menstruation

4. Self-reported lactose or fructose intolerance

5. Self-reported acute or chronic significant GI disease or digestion/absorption disorders (e.g. inflammatory bowel disease, coeliac disease, pancreatitis, disorders in digestive tract motility etc.)

6. Self-reported local anorectal problems (e.g. anal fissure, bleeding haemorrhoids)

7. Self-reported clinically significant findings in colonoscopy within the 2 years prior to study

8. Family history (immediate family) of colorectal cancer or inflammatory bowel disease; anxiety or depression requiring medication

9. Acute or chronic psychiatric disease (e.g. depression, anxiety, bipolar disorder) requiring medication

10. History and/or presence of other clinically significant condition/disorder, which per investigator's judgement could interfere with the results of the study or the safety

of the subject, e.g.:

• unstable thyroid gland disorder
• unstable hypertension
• unstable diabetes mellitus
• eating disorder
• immunodeficiency
• relevant gynecological or urological disorder
• any other relevant serious organ or systemic diseases (e.g. cardiovascular, liver, renal disease etc.)

11. Significant GI surgery within the last 6 months prior to or planned during the study

12. Regular medication and/or supplementation within the last month prior to and during

the study:

• antibiotics, probiotics, metformin
• for management of IBS complaints, such as bile acid binders (e.g. cholestyramine), rifaximin, alosetron, lubiprostone, eluxadoline, linaclotide, peppermint oil
• that could influence gastrointestinal functions (e.g. laxatives, opioids, systemic corticosteroids, anticho-linergics, anti-diarrheals etc.) as per investigator judgement

13. Regular use of psychotropic drugs (e.g. hypnotics / sedative drugs, anxiolytics, antidepressants, neuroleptics, anticonvulsants) within 3 months prior to study or adaptogens (e.g. ginseng, St. John's Wort) within 6 weeks prior to and during the study

14. Introductions of a specific diet (e.g. low carb, vegan, high-fibre, low FODMAP within last 3 months prior to and during the study

15. Women of child-bearing potential: pregnancy or nursing

16. History of or current abuse of drugs, alcohol or medication

17. Participation in another study during the last 30 days prior to and during the study

18. Any other reason for exclusion as per investigator's judgment, e.g. insufficient compliance with study procedures

Related Conditions & MeSH terms

• Irritable Bowel Syndrome
• Syndrome

Intervention

Dietary Supplement:
• pasteurized A. muciniphila
pasteurized A. muciniphila - oral daily dose
• placebo
Placebo = identical to verum regarding the form, size, taste, color and intake

Locations

Country	Name	City	State
Germany	analyze & realize GmbH	Berlin

Sponsors (1)

Lead Sponsor	Collaborator
A-Mansia Biotech S.A.

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Irritable Bowel Severity Scoring System / IBS-SSS	Changes at each timepoint of assessment in comparison to baseline. IBS-SSS is between 0 and 500, with a higher score meaning more severe symptoms.	From baseline to day 14, day 42 and day 84
Secondary	Irritable Bowel Syndrome-Global Improvement Scale / IBS-GIS	Changes at each timepoint of assessment in comparison to baseline. The IBS-GIS is a single item assessment of overall IBS symptoms. It poses the question to study participants "How would you rate your IBS signs or symptoms over the past 7 days": Subjects respond on a scale of 1-7 where: 1 = Significantly relieved, 2 = Moderately relieved, 3 = Slightly relieved, 4 = Unchanged, 5 = Slightly worse, 6 = Moderately worse, 7 = Significantly worse.	From baseline to day 14, day 42 and day 84
Secondary	3-day diary data on stool frequency	Changes at each timepoint of assessment in comparison to baseline	From baseline to day 84
Secondary	3-day diary data on stool consistency (Bristol Stool Form Scale / BSFS)	Changes at each timepoint of assessment in comparison to baseline. The Bristol Stool Form Scale is a 7 score visual scale to measure stool consistency. (1) Separate hard lumps like nuts (difficult to pass); (2) Sausage-shaped but lumpy; (3) Like a sausage but with cracks on its surface; (4) Like a sausage or snake, smooth and soft; (5) Soft blobs with clear-cut edges (passed easily); (6) Fluffy pieces with ragged edges, a mushy stool; (7) Watery, no solid pieces, entirely liquid.	From baseline to day 14, day 42 and day 84
Secondary	Hospital Anxiety and Depression Scale / HADS	Changes at each timepoint of assessment in comparison to baseline. The HADS is a fourteen item scale. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains. Patients were defined as having anxiety or depression or both if the score was 8 or more in the corresponding subscale.	From baseline to day 14, day 42 and day 84
Secondary	SF-12: 12-item Short Form survey	Changes at each timepoint of assessment in comparison to baseline. The SF-12 consists of 12 items questioned weighted and summed to provide physical and mental health scores (PCS and MCS). The two composite scores are computed using the scores on twelve questions that range from 0 to 100, with higher score indicating better health.	From baseline to day 42 and day 84
Secondary	Global evaluation of tolerability by subject and investigator	Changes in comparison to baseline. 8 weeks after the baseline, the subjects and the investigator will rate the tolerability of the IP by means of a global scaled evaluation with "very good", "good", "moderate" and "poor"	From baseline to day 84